Currently, there are two antifbrotics used to treat idiopathic pulmonary fbrosis (IPF): pirfenidone and nintedanib. Antifbrotics slow disease progression by reducing the annual decline of forced vital capacity (FVC), which possibly improves outcomes in IPF patients. |